Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial

by   Masahiro Kojima, et al.

Purpose: The early identification of maximum tolerated dose (MTD) in phase I trial leads to faster progression to a phase II trial or an expansion cohort to confirm efficacy. Methods: We propose a novel adaptive design for identifying MTD early to accelerate dose-finding trials. The early identification of MTD is determined adaptively by dose-retainment probability using a trial data via Bayesian analysis. We applied the early identification design to an actual trial. A simulation study evaluates the performance of the early identification design. Results: In the actual study, we confirmed the MTD could be early identified and the study period was shortened. In the simulation study, the percentage of the correct MTD selection in the early identification Keyboard and early identification Bayesian optimal interval (BOIN) designs was almost same from the non-early identification version. The early identification Keyboard and BOIN designs reduced the study duration by about 50 model-assisted designs. In addition, the early identification Keyboard and BOIN designs reduced the study duration by about 20 model-assisted designs. Conclusion: We proposed the early identification of MTD maintaining the accuracy to be able to short the study period.


page 23

page 24


Early completion based on multiple dosages to accelerate maximum tolerated dose-finding

Background: Phase I trials desire to identify the maximum tolerated dose...

Adaptive Cohort Size Determination Method for Bayesian Optimal Interval Phase I/II Design to Shorten Clinical Trial Duration

Recently, the strategy for dose optimization in oncology has shifted to ...

Introduction of accelerated BOIN design and facilitation of its application

Purpose: During discussions at the Data Science Roundtable meeting in Ja...

Data-Dependent Early Completion of Dose Finding Trials for Drug-Combination

We propose a data-dependent early completion of dose finding trials for ...

Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs

An objective of phase I dose-finding trials is to find the maximum toler...

Bayesian Multi-Arm De-Intensification Designs

In recent years new cancer treatments improved survival in multiple hist...

What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design

If explicit, formal consideration of clinical pharmacology at all inform...

Please sign up or login with your details

Forgot password? Click here to reset